Interestingly, SOCS1 could reduce PD-L1 expression and restore the activation of tumor-infiltrating CD8+ T cells, which highlighted its potential as an immune checkpoint inhibitor in OV (Nakagawa et al., 2018). The gene discussed is CD8A; the disease is neoplasm.